• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Corline Biomedical

18.00 SEK

+1.41 %

Less than 1K followers

CLBIO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.41 %
-1.64 %
+13.56 %
+9.76 %
+11.11 %
+82.93 %
+24.57 %
+57.89 %
+81.97 %

Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.

Read more
Market cap
470.4M SEK
Turnover
14.54K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
26.8.
2026

Interim report Q2'26

16.11.
2026

Interim report Q3'26

18.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release5/11/2026, 8:16 AM

Redeye: Corline Biomedical (Q1 Review): Encouraging signs of commercial acceleration

Corline Biomedical
Press release2/18/2026, 10:21 AM

Redeye: Corline Biomedical Q4 (Review): Case intact, but sales ramp-up needed to restore market confidence

Corline Biomedical
Press release11/19/2025, 7:25 AM

Redeye: Corline Biomedical Q3 (Review) - Sales growth incoming

Corline Biomedical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release9/2/2025, 8:29 AM

Redeye: Corline Biomedical - Kardium receives FDA approval

Corline Biomedical
Press release8/27/2025, 9:54 AM

Redeye: Corline Biomedical Q2 - Kardium’s Globe system nearing launch

Corline Biomedical
Press release5/11/2025, 3:51 PM

Redeye: Corline Biomedical Q1 - Exciting quarters ahead

Corline Biomedical
Press release2/18/2025, 7:34 AM

Redeye: Corline Biomedical Q4 - Focus on Kardium’s market launch

Corline Biomedical
Press release2/4/2025, 6:47 AM

Redeye: Redeye Initiates Coverage of Corline Biomedical

Corline Biomedical
Regulatory press release5/16/2019, 4:09 PM

Corline Biomedical AB: Will present at investor event hosted by Aktiespararna on June 3rd in Stockholm

Corline Biomedical